Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
BioNTech SE (BioNTech) is a biotechnology company that develops immunotherapies for cancer and infectious diseases. The company's primary activities involve harnessing the immune system to address diseases with unmet medical needs, utilizing a multi-technology innovation engine, GMP manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science, and artificial intelligence (AI) and machine learning (ML). Its major products encompass mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates and chimeric antigen receptor T cell therapies. The company’s marketed products are BNT162, BNT327. BioNTech collaborates with multiple global pharmaceutical companies, including Duality Biologics, Fosun Pharma, Genentech, Genevant, Genmab, OncoC4, Regeneron, and Pfizer, to enhance its research and development efforts. The company serves healthcare providers and patients by offering innovative immunotherapies and vaccines targeting cancer and infectious diseases. While the company operates globally, it aims to contribute to equitable access to medicine as part of its product strategy. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.
Headquarters
Germany
Address
An Der Goldgrube 12, Mainz, Rheinland-Pfalz, 55131
Website
www.biontech.com
Telephone
49 6131 90840
No of Employees
7,807
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BNTX (NASD)
Revenue (2024)
$3.2B
4.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-70.8%
(2024 vs 2023)
Market Cap*
$23.5B
Net Profit Margin (2024)
XYZ
-63.7%
(2024 vs 2023)
* As of and is in US$
BioNTech SE premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Marketed | Manufacturing Services | BioNTech |
| BNT162 | Diagnostics | Comirnaty |
| BNT 327 | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Plans/Strategy | In May, the company announced its plans to close its three sites in Germany and one in Singapore. |
| 2026 | Contracts/Agreements | In April, the company launched a Phase Ib/II trial with Boehringer Ingelheim to combine its DLL3-targeting T-cell engager obrixtamig and the PD-L1/VEGF-A bispecific antibody pumitamig in extensive-stage small-cell lung cancer. |
| 2025 | Acquisitions/Mergers/Takeovers | In December, the company acquired CureVac, a clinical-stage biotech company. |
Competitor Comparison
| Key Parameters | BioNTech SE | Argenx SE | Genmab AS | eTheRNA Immunotherapies NV |
|---|---|---|---|---|
| Headquarters | Germany | Netherlands | Denmark | Belgium |
| City | Mainz | Amsterdam | Valby | Niel |
| State/Province | Rheinland-Pfalz | Noord-Holland | - | - |
| No. of Employees | 7,807 | 1,599 | 2,682 | - |
| Entity Type | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Helmut Jeggle | Chairman | Executive Board | 2008 | 53 |
| Ugur Sahin, M.D. | Chief Executive Officer | Senior Management | 2008 | 58 |
| Ramon Zapata-Gomez | Chief Financial Officer | Senior Management | 2025 | 52 |
| Sierk Poetting | Chief Operating Officer | Senior Management | 2014 | 51 |
| James Ryan | Chief Business Officer; Chief Legal Officer | Senior Management | 2023 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer